VANCOUVER, BC, Jan. 5, 2021 /CNW/ - InMed
Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ: INM)
(TSX: IN), a clinical-stage pharmaceutical company developing
medications targeting diseases with high unmet medical need and
leading the clinical development of cannabinol ("CBN"), today
announced that InMed will be participating in the following virtual
investor and partnering conferences in January 2021.
H.C. Wainwright BioConnect Conference
Date: January 11-14th
Presentation Details: The company presentation
by Eric A. Adams, President and CEO
of InMed, will be available on demand beginning January 11th at 6am EST and can be found at the below link. The
presentation will be archived for 90 days following the conclusion
of the event.
BIO Partnering at JPM
Date: January 11-15th
To request a 1x1 meeting, please reach out to
Edison Open House: Global Healthcare
Date: January 26-28th
Presentation information will be made available closer to the
event. To register for the event and request a 1x1 meeting, please
reach out to email@example.com.
Information on each event, as well as links to presentations as
they become available, will be posted on InMed's event page, which
can be found at:
About InMed: InMed Pharmaceuticals is a clinical-stage
pharmaceutical company developing a pipeline of cannabinoid-based
medications, initially focused on the therapeutic benefits of
cannabinol ("CBN") in diseases with high unmet medical need. The
Company is dedicated to delivering new therapeutic alternatives to
patients that may benefit from cannabinoid-based medicines. For
more information, visit www.inmedpharma.com.
Cautionary Note Regarding Forward-Looking
This news release contains "forward-looking information" and
"forward-looking statements" (collectively, "forward-looking
information") within the meaning of applicable securities laws.
Forward-looking information is based on management's current
expectations and beliefs and is subject to a number of risks and
uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements.
Forward-looking information in this news release includes
statements about: participating in multiple conferences in
January 2021, including the H.C.
Wainwright BioConnect 2021 Conference, BIO Partnering at JPM 2021,
and Edison Open House Global Healthcare 2021; leading the way in
the clinical development of cannabinol (CBN); developing a pipeline
of cannabinoid-based medications in diseases with high unmet
medical need; and delivering new therapeutic alternatives to
patients that may benefit from cannabinoid-based medicines.
All forward-looking information herein is qualified in its
entirety by this cautionary statement, and InMed disclaims any
obligation to revise or update any such forward-looking information
or to publicly announce the result of any revisions to any of the
forward-looking information contained herein to reflect future
results, events or developments, except as required by law.
NEITHER THE TORONTO
STOCK EXCHANGE NOR ITS REGULATIONS
SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE
ADEQUACY OR ACCURACY OF THIS RELEASE.
SOURCE InMed Pharmaceuticals Inc.